Targeting mTORC2 inhibits colon cancer cell proliferation in vitro and tumor formation in vivo
<p>Abstract</p> <p>The mammalian target of rapamycin (mTOR), which exists in two functionally distinct complexes, mTORC1 and mTORC2 plays an important role in tumor growth. Whereas the role of mTORC1 has been well characterized in this process, little is known about the functions o...
Main Authors: | Demartines Nicolas, Dormond-Meuwly Anne, Cerantola Yannick, Roulin Didier, Dormond Olivier |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-03-01
|
Series: | Molecular Cancer |
Online Access: | http://www.molecular-cancer.com/content/9/1/57 |
Similar Items
-
Antitumor activities of ATP-competitive inhibitors of mTOR in colon cancer cells
by: Blaser Benjamin, et al.
Published: (2012-03-01) -
Targeting the Mammalian Target of Rapamycin (mTOR) in Cancer Therapy: Lessons from Past and Future Perspectives
by: Olivier Dormond, et al.
Published: (2011-05-01) -
Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
by: Xiao-Dong Pan, et al.
Published: (2017-01-01) -
Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
by: Seraina Faes, et al.
Published: (2021-03-01) -
Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy
by: Seraina Faes, et al.
Published: (2017-11-01)